Abstract 152P
Background
Adenosine accumulates in the tumor microenvironment due to abnormal tumor metabolism and hypoxia. It binds to A2A and A2B receptors on immune cells and impairs their activation and cytotoxic ability, helping cancers to evade the immune system and resist cancer therapies. Adenosine receptor antagonists that act in pathological concentrations of adenosine can rescue T cell and innate immune suppression and improve the efficacy of existing treatments.
Methods
We used structure-guided medicinal chemistry to design adenosine antagonists and measured how well they bind to A2A and A2B receptors in cells using HTRF and Tag-lite technology. Their ability to block adenosine’s effect on primary immune cells was monitored by measuring CREB phosphorylation and cytokine production. In vitro coculture assays and syngeneic mouse models were used to check the effect of immune response and tumor growth. We also used a patient-derived ex vivo tumor platform to demonstrate clinical translatability.
Results
BWC2094 is a potent A2A receptor antagonist, while BWC2562 is a potent A2A/A2B dual antagonist in a high adenosine environment. They selectively bind A2A at picomolar concentrations and had >50-fold selectivity over A1 and A3 receptors. They reduced the phosphorylation of CREB and restored the production of cytokines, such as IL2, TNFα and IFNγ in adenosine-suppressed immune cells. The lead compounds exhibited a synergistic effect with standard of care drugs in co-culture assays of tumor cells and PBMC. Both, BWC2094 and BWC2562 demonstrated good oral bioavailability in rodents (>25 %F) and dogs (>50 %F) and are well tolerated for 14 days in rat acute toxicity study. At a dose of 3mg/kg, they reduce the tumor volume as monotherapy and enhanced the anti-tumor effects of anti-PD1/PDL1 and CTLA4 in CT26, MC38, and MCA205 murine tumor models. In a patient-derived ex vivo tumor model, Precision immunotherapy using Complementary approaches in Systems Oncology (PiCaSO), they reduced tumor density, decreased Ki67 expression and increased apoptosis/necrosis.
Conclusions
BWC2094 and BWC2562 can block the immunosuppressive effects of adenosine and improve the effectiveness of existing therapies in oncology.
Legal entity responsible for the study
The authors.
Funding
Bugworks Research Inc.
Disclosure
N. Katagihallimath, R. Nandishaiah, S. Sharma, S. Venkatesan, R. Rao, N. Bharatham, M. Gupta, D. Kundu, H. Kaushik Kotakonda, R. Ramalingam Kalainesan, S. Reddy, B. Tewary, L. Maitreyi, B. Venkatraman, S. V Rekha Sody, B. Majumder: Financial Interests, Personal and Institutional, Stocks/Shares: Bugworks. S. Datta, S.Hameed: Financial Interests, Personal and Institutional, Stocks or ownership: Bugworks. All other authors have declared no conflicts of interest.
Resources from the same session
111P - Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
Presenter: Ciro Celsa
Session: Poster Display
112P - Close cardiovascular monitoring during the early stages of treatment for patients receiving immune checkpoint inhibitors
Presenter: Danielle Delombaerde
Session: Poster Display
113P - A multidisciplinary management of immune-checkpoint inhibitor (ICI)-related pneumonitis to improve its clinical management
Presenter: Monica Valente
Session: Poster Display
114P - Real-World Insights on Pan-Cancer Immune Checkpoint Inhibitor Treatment: Initial Findings of a Belgian Multicenter Study
Presenter: Annelies Verbiest
Session: Poster Display
115TiP - MDT-BRIDGE: A phase 2 study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC
Presenter: Martin Reck
Session: Poster Display
117TiP - BGB-HNSCC-201 (NCT05909904): Phase 2, Open-Label, Multi-Arm, Global Study of Tislelizumab (TIS) + Investigational Agents as First-Line (1L) Treatment in Patients (Pts) With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Presenter: Kevin Harrington
Session: Poster Display
121P - MK-7684A (Vibostolimab [Vibo] Plus Pembrolizumab [Pembro] Coformulation) With/Without Docetaxel in Metastatic NSCLC After Platinum-Chemotherapy (Chemo) and Immunotherapy
Presenter: Nir Peled
Session: Poster Display
123P - A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: the run-in phase of the NIBIT Foundation ML1 Study
Presenter: Anna Di Giacomo
Session: Poster Display
124P - Surufatinib plus toripalimab combined with etoposide (E) and cisplatin (P) in patients (pts) with advanced naive small cell lung cancer (SCLC) -Updated results of a phase ?b/? trial
Presenter: Wen Feng Fang
Session: Poster Display